UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 211

Sortiert nach

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.727-731

Holmes, F.A.

2002

Volltextzugriff (PDF)

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

Annals of oncology, 2002-06, Vol.13 (6), p.903-909

2002

Volltextzugriff (PDF)

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Annals of oncology, 2006-09, Vol.17 (9), p.1379-1385

2006

Volltextzugriff (PDF)

Angiofollicular lymph node hyperplasia (Castleman's disease)

Cancer Treatment Reviews, 1995-07, Vol.21 (4), p.291-310

1995

Volltextzugriff (PDF)

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

Journal of clinical oncology, 2002-06, Vol.20 (12), p.2812-2823

2002

Volltextzugriff (PDF)

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2015-07, Vol.373 (3), p.209-219

2015

Volltextzugriff (PDF)

Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With Taxotere

JNCI : Journal of the National Cancer Institute, 1993-09, Vol.85 (17), p.1432-1433

1993

Volltextzugriff (PDF)

Cellular immune profile of patients with advanced cancer before and after taxane treatment

American journal of clinical oncology, 2000-10, Vol.23 (5), p.463-472

2000

Volltextzugriff (PDF)

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

European journal of cancer supplements, 2009, Vol.7 (2), p.266-267

2009

Volltextzugriff (PDF)

Azathioprine as a Steroid-Sparing Agent in Radiation Pneumonitis

Chest, 1996-05, Vol.109 (5), p.1397-1400

1996

Volltextzugriff (PDF)

Gilbert's syndrome co-existing with and masking hereditary spherocytosis

Annals of hematology, 1997-06, Vol.74 (6), p.287-289

1997

Volltextzugriff (PDF)

Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea

American journal of hematology, 1996-02, Vol.51 (2), p.137-140

1996

Volltextzugriff (PDF)

Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer

Molecular therapy, 2006-06, Vol.13 (6), p.1185-1191

2006

Volltextzugriff (PDF)

Lymphomatoid papulosis associated with Ki‐1‐positive anaplastic large cell lymphoma. A report of two cases and a review of the literature

Cancer, 1994-12, Vol.74 (11), p.3051-3058

1994

Volltextzugriff (PDF)

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.727-731

2002

Volltextzugriff (PDF)

High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer : long-term results

Bone marrow transplantation (Basingstoke), 1998-04, Vol.21 (8), p.775-778

1998

Volltextzugriff (PDF)

Chemotherapy of disseminated Merkel-cell carcinoma

American journal of clinical oncology, 1991-08, Vol.14 (4), p.305-307

1991

Volltextzugriff (PDF)

Diffuse alveolar hemorrhage following autologous bone marrow infusion

Bone marrow transplantation (Basingstoke), 1993-09, Vol.12 (3), p.301

1993

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7825-7833

2005

Volltextzugriff (PDF)

Unusual serpentine hyperpigmentation associated with 5-fluorouracil : Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil

Journal of the American Academy of Dermatology, 1991-11, Vol.25 (5), p.905-908

1991

Volltextzugriff (PDF)

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-18-09

2011

Volltextzugriff (PDF)

Incidence of and Predictive Factors for Recovery of Ovarian Function on Letrozole in ER-Positive Breast Cancer Patients in Their Forties Who Cease Menstruating with Adjuvant Chemotherapy

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.6097-6097

2009

Volltextzugriff (PDF)

Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC)

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.5099-5099

2009

Volltextzugriff (PDF)

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.500-500

2011

Volltextzugriff (PDF)

Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1016-1016

2010

Volltextzugriff (PDF)

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(193)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(207)
Croatian
(13)
Japanisch
(11)
Deutsch
(2)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(89)
Science & Technology
(88)
Life Sciences & Biomedicine
(74)
Female
(61)
Middle Aged
(59)
Oncology
(51)
Adult
(48)
Aged
(47)
Biological And Medical Sciences
(46)
Medical Sciences
(46)
Male
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(34)
Breast Neoplasms - Drug Therapy
(30)
Treatment Outcome
(24)
Aged, 80 And Over
(21)
Breast Neoplasms - Pathology
(21)
Chemotherapy
(18)
Tumors
(18)
Breast Cancer
(14)
Follow-Up Studies
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Angiofollicular lymph node hyperplasia (Castleman's disease)

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With Taxotere

Cellular immune profile of patients with advanced cancer before and after taxane treatment

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

Azathioprine as a Steroid-Sparing Agent in Radiation Pneumonitis

Gilbert's syndrome co-existing with and masking hereditary spherocytosis

Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea

Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer

Lymphomatoid papulosis associated with Ki‐1‐positive anaplastic large cell lymphoma. A report of two cases and a review of the literature

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer : long-term results

Chemotherapy of disseminated Merkel-cell carcinoma

Diffuse alveolar hemorrhage following autologous bone marrow infusion

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Unusual serpentine hyperpigmentation associated with 5-fluorouracil : Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim

Incidence of and Predictive Factors for Recovery of Ovarian Function on Letrozole in ER-Positive Breast Cancer Patients in Their Forties Who Cease Menstruating with Adjuvant Chemotherapy

Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC)

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses

Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy

Suchergebnisse filtern